Bettcher Brianne M, Neuhaus John, Wynn Matthew J, Elahi Fanny M, Casaletto Kaitlin B, Saloner Rowan, Fitch Ryan, Karydas Anna, Kramer Joel H
Rocky Mountain Alzheimer's Disease Center, Departments of Neurosurgery and Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, United States.
Front Aging Neurosci. 2019 Feb 13;11:25. doi: 10.3389/fnagi.2019.00025. eCollection 2019.
: To determine the longitudinal relationship between monocyte chemotactic protein 1 (MCP-1)/CCL2 and memory function in older adults. : We examined longitudinal plasma MCP-1/CCL2 levels and a longitudinal verbal memory measure (CVLT-II 20' recall) in a sample of 399 asymptomatic older adults (mean age = 72.1). Total visits ranged from 1 to 8, with an average time of 2.1 years between each visit, yielding 932 total observations. In order to isolate change over time, we decomposed MCP-1/CCL2 into subject-specific means and longitudinal deviations from the mean. The decomposed MCP-1/CCL2 variables were entered as predictors in linear mixed effects models, with age at baseline, sex, and education entered as covariates and recall as the longitudinal outcome. In follow-up analyses, we controlled for global cognition and genotype, as well as baseline vascular risk factors. We also examined the specificity of findings by examining the longitudinal association between the MCP-1/CCL2 variables and non-memory cognitive tests. : Within-subject increases in MCP-1/CCL2 levels were associated with decreases in delayed recall ( = -2.65; = 0.01) over time. Results were independent of global cognitive function and APOE status ( = -2.30, = 0.02), and effects remained when controlling for baseline vascular risk factors ( = -1.92, = 0.05). No associations were noted between within-subject increases in MCP-1/CCL2 levels and other cognitive domains. : In an asymptomatic aging adult cohort, longitudinal increases in MCP-1/CCL2 levels were associated with longitudinal decline in memory. Results suggest that "healthy aging" is typified by early remodeling of the immune system, and that the chemokine, MCP-1/CCL2, may be associated with negative memory outcomes.
确定老年人单核细胞趋化蛋白1(MCP-1)/CCL2与记忆功能之间的纵向关系。
我们在399名无症状老年人(平均年龄=72.1岁)样本中检测了纵向血浆MCP-1/CCL2水平和纵向言语记忆测量指标(CVLT-II 20分钟回忆)。总访视次数从1次到8次不等,每次访视之间的平均时间为2.1年,共产生932次观察结果。为了分离随时间的变化,我们将MCP-1/CCL2分解为个体特异性均值和相对于均值的纵向偏差。分解后的MCP-1/CCL2变量作为预测因子纳入线性混合效应模型,将基线年龄、性别和教育程度作为协变量,回忆作为纵向结局。在后续分析中,我们控制了整体认知和基因型以及基线血管危险因素。我们还通过检查MCP-1/CCL2变量与非记忆认知测试之间的纵向关联来检验研究结果的特异性。
随着时间的推移,MCP-1/CCL2水平的个体内升高与延迟回忆的降低相关(β=-2.65;P=0.01)。结果独立于整体认知功能和APOE状态(β=-2.30,P=0.02),在控制基线血管危险因素后效应仍然存在(β=-1.92,P=0.05)。未发现MCP-1/CCL2水平的个体内升高与其他认知领域之间存在关联。
在无症状老年人群队列中,MCP-1/CCL2水平的纵向升高与记忆的纵向下降相关。结果表明,“健康衰老 ”的典型特征是免疫系统的早期重塑,趋化因子MCP-1/CCL2可能与记忆不良结局有关。